LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
- Read more about LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/lintonpharm-announces-first-patient-dosed-in-phase-1-clinical-trial-of-catumaxomab-for-non-muscle-invasive-bladder-cancer-unresponsive-to-bacillus-calmette-guerin
No comments:
Post a Comment